Early-Onset Diabetes Increases Mortality Risk

People who develop type 2 diabetes before the age of 40 are significantly more likely to die early than those diagnosed after 60, according to a new analysis.
The study adds weight to previous research that suggests early-onset diabetes may be a more aggressive form of the condition, say scientists. However, these findings have only included small groups of people.
The latest research drew on data from 2,706,820 people in England aged 20 and older diagnosed with type 2 diabetes after 2008 and included in the National Diabetes Audit. These individuals were cross-referenced with death register entries up to December 2015.

Risk Factors
Results showed that, after taking account of people's age and sex, individuals diagnosed with type 2 diabetes before the age of 40 were almost two-and-a-half times more likely to die early than those diagnosed after the age of 60.

They also showed that:
· People diagnosed before the age of 40 had higher body mass index (BMI) (33.5 compared with 2…

FDA Approves AliveCor Personal ECG Monitor for Apple Watch

The Food and Drug Administration has approved a wrist-worn version of the groundbreaking KardiaMobile from AliveCor, the company has announced. It's the next step in AliveCor's bid to do for the Apple Watch what it did for the iPhone: turn it into a single-channel ECG monitor.

The new AliveCor product, KardiaBand, is a wristband for the Apple Watch equipped with a sensor the user presses with a thumb. Via the company's Kardia mobile app, the ECG and heart rate are soon displayed on the watch's screen.

"This is a paradigm shift for cardiac care as well as an important advance in healthcare," Dr Ronald P Karlsberg (David Geffen School of Medicine, University of California, Los Angeles) is quoted as saying in the company announcement. "With an [ECG] device on the wrist, afib can be detected wherever the patient is, 24 hours a day." Users must subscribe to a $99/year service to use the KardiaBand system, the company notes in its announcement. That all…

Amsterdam to Host EU Drug Agency

BRUSSELS (Reuters) - Amsterdam won the right to host the EU's EMA drug agency when it leaves London after Brexit after the Dutch city tied with Milan in a vote on Monday that was then decided by the drawing of lots, diplomatic sources said.

 The Council of the European Union confirmed the choice of Amsterdam to host the European Medicines Agency (EMA) but gave no official account of the three rounds of vote which ended with disappointment for the Italian favourite in a lucky dip. The outcome was welcomed by European pharmaceuticals bodies.
 The EMA had warned that many of its staff might quit, possibly disrupting healthcare in Europe, if governments had chosen a less attractive host city, notably in the ex-communist east. Eastern governments were left empty-handed when a first round of voting among eight candidates to host the European Banking Authority (EBA) snubbed Warsaw and Prague. Paris, Frankfurt and Dublin went through to the second round, diplomats said, with Paris only sl…

Botox Injections to the Heart?

New research suggests epicardial botulinum toxin injections may reduce the all-too-common complication of postoperative atrial fibrillation (POAF), known to increase morbidity and affect 30% to 50% of patients after cardiac surgery.

The researchers turned to the neurotoxin, which reduces the release of acetylcholine from nerve terminals, because of the role autonomic imbalance plays in the development of AF. When injected near cardiac autonomic nerves in epicardial fat pads, botulinum toxin acts in an anticholinergic fashion on the atrium, shortening atrial effective refractory periods and blocking induction of AF, explained author and anesthesiologist Dr Nathan Waldron (Duke University School of Medicine, Durham, NC).

more: Medscape

News from American Heart Association Scientific Sessions (AHA) 2017/Hypertension

New ACC/AHA Hypertension Guidelines Make 130 the New 140

The American College of Cardiology (ACC) and the American Heart Association (AHA) have released a new guideline on hypertension with a new definition that will call 130 to 139 mm Hg systolic and or 80 to 89 mm Hg stage 1 hypertension.

"Lifestyle modification is the cornerstone of the treatment of hypertension. Specific recommendations include advice to lose weight, follow a DASH-pattern diet, reduce sodium to less than 1500 mg/day and increase potassium intake to 3500 mg/day through dietary intake, increase physical activity to a minimum of 30 minutes of exercise three times per week, and limit alcohol intake to two drinks or less per day for men and one or less for women.


Optical Coherence Tomography: Modest Benefit in PCI

ROME, ITALY — The first randomized trial to investigate the use of optical coherence tomography (OCT) in PCI has suggested that the procedure is safe and may be associated with some benefit[1].

The DOCTORS study was presented today at the European Society of Cardiology (ESC) 2016 Congress and simultaneously published online in Circulation.
The OCT technology visualizes the artery and stent placements, allowing the operator to make alterations on stent expansions and positioning. The intravascular procedure allows improved plaque characterization and can lead to improvements in lesion coverage, stent expansion, or apposition, explained lead investigator Dr Nicolas Meneveau (University Hospital Jean Minjoz, Besançon, France). Downsides of its use include prolonged procedural time and higher exposure to contrast media, as well as the cost issue.
The main result of DOCTORS study showed a modest 2-point improvement in fractional flow reserve (FFR) in NSTEMI patients undergoing PCI gui…

Gene discovery points to new treatments for heart disease

The findings could also lead to new treatments for other common diseases.

A gene discovery could pave the way for the development of new treatments for heart disease, after researchers found that it is responsible for blood vessel formation, or angiogenesis. The findings have resulted from an international research collaboration part-funded by the British Heart Foundation (BHF). The paper was published in the journal Nature Communications.

Researchers found that when they turned off the gene, called Wars2, in rats and zebrafish, there was reduced blood vessel growth both in the heart and throughout the rest of the body. This has confirmed the vital role of the Wars2 gene in blood vessel formation.

The Wars2 gene has previously been linked to obesity and cancer in large genetic studies, known as Genome Wide Association Studies (GWAS), which look for versions of genes which are common among people with a disease. Researchers are able to see if a gene is associated with a particular co…